XGN Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

17.26M

+26.43%

-0.189

-5.72%

17.89M

+15.41%

-0.166

-17.15%

19.46M

+13.11%

-0.121

-42.18%

Estimates Revision

The market is revising Downward the revenue expectations for Exagen Inc. (XGN) for FY2025, with the revenue forecasts being adjusted by -0.67% over the past three months. During the same period, the stock price has changed by -44.31%.

Revenue Estimates for FY2025

Revise Downward

-0.67%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+31.55%

In Past 3 Month

Stock Price

Go Down

-44.31%

In Past 3 Month

7 Analyst Rating

Wall Street analysts forecast XGN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for XGN is 16.20 USD with a low forecast of 15.00 USD and a high forecast of 18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

7 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

15.00

Averages

16.20

High

18.00

Current: 0.000

Low

15.00

Averages

16.20

High

18.00

TD Cowen

Buy

downgrade

$18 -> $13

2026-01-07

New

Reason

TD Cowen

Price Target

$18 -> $13

2026-01-07

New

downgrade

Buy

Reason

TD Cowen lowered the firm's price target on Exagen to $13 from $18 and keeps a Buy rating on the shares. The firm adjusted targets in the diagnostics group as part of a Q4 preview. It expects solid results and 2026 outlooks for the sector, saying strong fundamentals remain.

BTIG

Buy

maintain

$13 -> $15

2025-11-10

Reason

BTIG

Price Target

$13 -> $15

2025-11-10

maintain

Buy

Reason

BTIG raised the firm's price target on Exagen to $15 from $13 and keeps a Buy rating on the shares after its Q1 results. The company is driving a solid balance of volume and pricing gains, and is nearing positive adjusted EBITDA, the analyst tells investors in a research note.

B. Riley

Buy

upgrade

$15 -> $18

2025-11-05

Reason

B. Riley

Price Target

$15 -> $18

2025-11-05

upgrade

Buy

Reason

B. Riley raised the firm's price target on Exagen to $18 from $15 and keeps a Buy rating on the shares. The firm views the company's Q3 results as mixed but expects continued volume growth.

Canaccord

Buy

maintain

$11 -> $15

2025-10-27

Reason

Canaccord

Price Target

$11 -> $15

2025-10-27

maintain

Buy

Reason

Canaccord raised the firm's price target on Exagen to $15 from $11 and keeps a Buy rating on the shares. The firm updated its model ahead of Q3 results noting that the life science tools secot remains challenged amid multiple headwinds including tariffs, funding uncertainty, and China issues.

KeyBanc

Overweight

maintain

$12 -> $15

2025-10-14

Reason

KeyBanc

Price Target

$12 -> $15

2025-10-14

maintain

Overweight

Reason

KeyBanc raised the firm's price target on Exagen to $15 from $12 and keeps an Overweight rating on the shares. The firm is raising its FY25 and FY26 estimates, as KeyBanc believes visibility on revenue is increasing. Exagen's management team increased test reimbursement 27% in 2024 to $398 with increased sales discipline and recent administrative law judge wins also boosting commercial diagnostic reimbursement. With a $650 long-term pricing goal, KeyBanc views Exagen as well positioned to exceed consensus.

B. Riley

Anderson Schock

initiated

$15

2025-09-11

Reason

B. Riley

Anderson Schock

Price Target

$15

2025-09-11

initiated

Reason

B. Riley analyst Anderson Schock initiated coverage of Exagen with a Buy rating and $15 price target, reflecting 50% potential upside. Exagen is a diagnostics company that develops blood tests to help rheumatologists diagnose autoimmune diseases, the analyst tells investors in a research note. The firm believes the company's AVISE CTD is well positioned to become the \"gold standard\" for both lupus and rheumatoid arthritis diagnosis.

Valuation Metrics

The current forward P/E ratio for Exagen Inc (XGN.O) is -10.39, compared to its 5-year average forward P/E of -5.37. For a more detailed relative valuation and DCF analysis to assess Exagen Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-5.37

Current PE

-10.39

Overvalued PE

-0.16

Undervalued PE

-10.58

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-14.19

Current EV/EBITDA

-53.92

Overvalued EV/EBITDA

14.59

Undervalued EV/EBITDA

-42.97

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

2.04

Current PS

1.83

Overvalued PS

3.54

Undervalued PS

0.53

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

XGN News & Events

Events Timeline

No data

News

4.0

2025-12-08Yahoo Finance

New Factors Influencing Exagen's Story

4.0

2025-11-10Benzinga

BTIG Reaffirms Buy Rating on Exagen, Increases Price Target to $15

4.0

2025-10-27Benzinga

Booking Holdings Expected to Surge by 12%? Check Out 10 Leading Analyst Predictions for Monday

People Also Watch

Frequently Asked Questions

What is Exagen Inc (XGN) stock price today?

The current price of XGN is 6.17 USD — it has increased 2.49 % in the last trading day.

What is Exagen Inc (XGN)'s business?

Exagen Inc. is a provider of autoimmune diagnostics focused on transforming care for patients with chronic and debilitating autoimmune conditions. The Company is focused on the design, development and commercialization of a portfolio of testing products under its AVISE brand, which allow for the differential diagnosis, prognosis and monitoring of complex rheumatic, autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its testing products are supported by two proprietary technologies: its AVISE Lupus platform, which incorporates Cell-Bound Complement Activation Products (CB-CAPs) for diagnosing SLE, and a set of three biomarkers, the t-cell-based CB-CAP TC4d, along with two t-cell antibodies, TIgG, and TIgM (the T-Cell Biomarkers), all of which are incorporated into its AVISE CTD product. The Company’s flagship product, AVISE CTD, enables clinicians to more effectively diagnose complex autoimmune conditions.

What is the price predicton of XGN Stock?

What is Exagen Inc (XGN)'s revenue for the last quarter?

Exagen Inc revenue for the last quarter amounts to 17.24M USD, increased 37.87 % YoY.

What is Exagen Inc (XGN)'s earnings per share (EPS) for the last quarter?

Exagen Inc. EPS for the last quarter amounts to -0.31 USD, increased 10.71 % YoY.

What changes have occurred in the market's expectations for Exagen Inc (XGN)'s fundamentals?

How many employees does Exagen Inc (XGN). have?

Exagen Inc (XGN) has 203 emplpoyees as of January 09 2026.

What is Exagen Inc (XGN) market cap?

Today XGN has the market capitalization of 139.83M USD.